Skip to main content

Table 4 Cases and direct costs by pneumococcal infections vaccinating with PCV13, PPSV23, or not vaccine in people over 50 years in Colombia

From: Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia

Parameters PCV13 PPSV23 No vaccination (NV) PCV13-PPSV23 PCV13-NV
Number of cases      
Bacteremia 34 934 39 809 49 857 −4 875 (−12.2%) −14 923 (−29.9%)
Meningitis 2 306 2 557 3 135 −252 (−9.8%) −830 (−26.5%)
Inpatient pneumonia 439 971 496 752 496 795 −56 781 (−11.4%) −56 824 (−11.4%)
Outpatient pneumonia 841 546 864 397 866 189 −22 852 (−2.6%) −24 644 (−2.8%)
Deaths by pneumococcal infections 29 726 33 285 33 980 −3 560 (−10.7%) −4 255 (−12.5%)
LYG 11 377 2 290 0 9 087 11 377
Total costs (million)      
Medical costs U.S. $ 1,286.2 U.S. $ 1,439.7 U.S. $ 1,534.9   
Vaccine costs U.S. $ 103.6 U.S. $ 47.6 --   
Total U.S. $ 1,389.8 U.S. $ 1,487.3 U.S. $ 1,534.9 U.S. $ -97.5 U.S. $ -145.1